Caspases and neurodegeneration: A potential therapeutic target

Current Opinion in Central and Peripheral Nervous System Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 417-422

  Schulz, J B ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Caspases; IL 1 converting enzyme; Multiple sclerosis; Neurodegeneration; Stroke

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; CASPASE; CASPASE 3; CASPASE 9; CASPASE INHIBITOR; CV 1013; DIZOCILPINE; HUNTINGTIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; L 826791; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; PROTEIN P35; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN INJURY; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; HEPATITIS; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NEUROGENIC INFLAMMATION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; REVIEW; SPINAL CORD INJURY; STROKE;

EID: 0033856475     PISSN: 1464844X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia
2. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury
3. Activation of CPP32-like caspases contributes to neuronal apopotosis and neurological dysfunction after traumatic brain injury
4. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution
5. Caspase structure, proteolytic substrates, and function during apoptotic cell death
6. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis
7. A combinatorial approach for determining protease specificities: Application to interleukin-1β converting enzyme (ICE)
8. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
9. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
10. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
11. Histochemical detection of apoptosis in Parkinson's disease
12. Apoptotic-like changes in Lewy-body associated disorders and normal aging in substantia nigral neurons
13. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
14. On the question of apoptosis in the parkinsonian substantia nigra
15. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
16. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
17. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
18. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic A β peptide formation
19. Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury
20. DNA fragmentation in granular cells of human cerebellum following global ischemia
21. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease
22. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain
23. Patterns of oligodendroglia pathology in multiple sclerosis
24. Multiple sclerosis: Fas signaling in oligodendrocyte cell death
25. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain
26. DNA damage consistent with apoptosis in transient focal ischaemic neocortex
27. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus
28. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia
29. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family
30. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage
31. A caspase inhibitor blocks ischaemia-induced delayed neuronal death in the gerbil
32. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation
33. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia
34. Synergistic effects of caspase inhibitors an MK-801 in brain injury after transient focal cerebral ischemia in mice
35. Adenovirus-mediated gene transfer of IAPs delays apoptosis of cerebellar granule neurons
36. IAP family proteins - suppressors of apoptosis
37. Neuroprotection by the inhibition of apoptosis
38. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus
39. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury
40. Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade
41. Inhibition of interleukin-1β converting enzyme family proteases (caspases) reduces cold injury-induced brain trauma and DNA fragmentation in mice
42. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury
43. Inhibition of CPP32-like proteases rescues axotomized retinal ganglion cells from secondary cell death in vivo
44. Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination
45. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
46. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
47. Caspase-9 can be activated without proteolytic processing
48. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
49. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinium-induced toxicity of cultured fetal rat mesencephalic dopamine neurons
50. MPTP neurotoxicity is attenuated in mice overexpressing Bcl-2
51. Transgenic mice expressing a dominant negative mutant interleukin-1β converting enzyme show resistance to MPTP neurotoxicity
52. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
53. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischemia in the rat
54. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat
55. Attenuation of transient focal cerebral ischemia injury in transgenic mice expressing a mutant ICE inhibitory protein
56. Inhibition of ICE slows ALS in mice
57. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
58. Programmed cell death regulation: Basic mechanisms and therapeutic opportunities (Part II), Lake Tahoe, NV, USA
59. Caspases in apoptotic death